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Abstract
Background: Elderly individuals with type 2 diabetes mellitus (T2DM) suffer from several comorbidities, which
affect their health outcomes, as well as process of care. This study assessed process and intermediate clinical
outcomes of diabetes care among elderly individuals with T2DM and co-occurring Parkinson’s disease(PD).
Methods: This study used a retrospective cohort design with propensity score matching using Humana Medicare
Advantage Part D claims database (2007-2011) and included elderly (age ≥ 65 years) Medicare beneficiaries with
T2DM (identified by ICD-9-CM code of 250.x0 or 250.x2). PD was identified using ICD-9-CM code of 332.xx. After
propensity score matching there were 2,703 individuals with T2DM and PD and 8,109 with T2DM and no PD. The
three processes of care measures used in this study included: (i) HbA1c test; (ii) Lipid test; (iii) and Nephropathy
screening. Intermediate clinical outcomes consisted of glycemic and lipid control.
Results: Multivariable conditional logistic regressions revealed that elderly individuals with T2DM and PD were 12
% (AOR: 0.88, 95 %CI: 0.79-0.97) and 18 % (AOR: 0.82, 95 %CI: 0.72-0.94) less likely to meet the annual American
Diabetes Association (ADA) recommended HbA1c and lipid testing goals respectively compared to individuals with
T2DM and no PD. Multinomial conditional logistic regressions showed that elderly individuals with T2DM and PD
were more likely to have HbA1c and lipid (HbA1c < 8 %; LDL-C <100 mg/dl; HDL-C ≥ 50 mg/dl; triglyceride <150
mg/dl; and total cholesterol <200 mg/dl) control.
Conclusions: Among elderly individuals with T2DM, those with PD were less likely to achieve ADA recommended
annual HbA1c and lipid testing compared to those without PD. However, PD individuals were more likely to
achieve intermediate glycemic and lipid control.
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Introduction
Type-2 Diabetes Mellitus (T2DM) and its complications
are the leading causes for morbidity and mortality in the
United States (U.S.) [1]. Parkinson’s disease (PD) is a pro-
gressive neurodegenerative disease characterized by muscu-
lar tremor, slowing of movement, partial facial paralysis,
peculiarity of gait and posture [2, 3]. Individuals with co-
occurring T2DM and PD can have poor quality of life, im-
paired health and functional status. Moreover, co-occurring
T2DM and PD require medical care from different
specialties such as neurologists and endocrinologist, and re-
quire care in different settings including home-based as
well as facility-based care [4]. Co-occurring T2DM and PD
can pose significant challenges to diabetes management.
However, clinical guidelines for diabetes management
for those with T2DM and PD are lacking. In general,
guidelines for clinical practice are developed based on
the expert consensus and the scientific evidence for a
single disease state [5]. Standards of care and quality of
care improvement efforts are based on these guidelines
for clinical practice for individual disease state. As for
example, there are separate guidelines for treating dia-
betes (such as the guidelines of the American Diabetes* Correspondence: bhattacharjee@pharmacy.arizona.edu1Department of Pharmacy Practice and Science, School of Pharmacy, The
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Association) and PD (European Parkinson’s disease
Standards of Care Consensus Statement).
Studies on diabetes care among individuals with other
co-occurring chronic conditions have revealed mixed
findings. One study conducted among veterans with dia-
betes seeking care in seven different Veterans Affairs
(VA) facilities from July 2007 through June 2008 reported
that veterans with T2DM were more likely to receive over-
all good quality for all three quality measures (glycemic,
blood pressure and low density lipoprotein-cholesterol
control) combined (adjusted OR, 2.17; 95 % CI, 1.96–2.39)
[6]. Whereas, another study using the INTERMED classi-
fication system for case complexity found that greater
complexity (defined as higher INTERMED scores) among
individuals with T2DM was associated with higher HbA1c
values [7]. Therefore, it is not known whether clinical
complexity is associated with poor or better outcomes
among individuals with T2DM.
Despite there being no separate guideline recommenda-
tions regarding diabetes process of care (e.g., bi-annual
HbA1c testing) in the presence of neurodegenerative con-
ditions, it can be perceived that meeting at least the usual
diabetes process of care recommendations is critical to
providing appropriate care to elderly individuals with
T2DM and PD. However, to the best of our knowledge,
no prior study have explored the diabetes process of care
among elderly individuals with co-occurring T2DM and
PD. The results from the current study will fill a critical
knowledge gap regarding the current standards of care
among individuals with co-occurring T2DM and PD.
A study of diabetes management among elderly with
T2DM and PD is important for several reasons. It has
been estimated that by 2030, the prevalence of PD will
increase by approximately two-folds due to the aging
U.S. population [8] and will become a major public
health concern in near future. Moreover, existing litera-
ture suggests that the presence of T2DM aggravates
neurodegeneration and therefore there is a need of con-
trolling T2DM to prevent further deterioration [9–11].
Hence, the primary aim of this study is to assess the
process and intermediate clinical outcomes of diabetes
care among elderly individuals with T2DM and PD com-
pared to those with T2DM and no PD.
Methods
Study design
A retrospective cohort design with matched case–control
approach was used for the purposes of this study. Those
with T2DM and PD were considered as cases and those
with T2DM and no PD were considered as controls. Con-
trols were selected using propensity score method, which
adjusted for gender, age, and diabetes complications sever-
ity index (DCSI). The algorithm developed by Chang and
colleagues was used to measure the severity of diabetes
using DCSI [12]. One case was matched to three controls
based on 8 to 1 GREEDY matching technique using pro-
pensity score. For 8 to 1 GREEDY matching, the cases
and control with same propensity score till the 8th digit
are matched, and if they do not match on 8 digits, then it
goes to 7-digit matching and so on. The GREEDY match-
ing technique employs a sample without replacement
algorithm and if there are more than one matches, then
selection of control becomes random. Similar approach
for propensity score matching have been used in existing
literature to minimize the effect of bias and confounding
[13]. Controls were selected from the same calendar year
as the cases; if individuals were identified with PD in 2008,
all controls were from 2008. If elderly Medicare benefi-
ciaries did not have PD in the initial years and then devel-
oped it later during the study time period, they were
removed from the control pool.
Elderly individuals with T2DM were followed for a
period of 24 months with 12-month baseline period and
12 month follow-up period. Baseline period was defined
based on the identification of T2DM and PD. For example,
if T2DM and PD cases were identified in 2007, 2007 served
as the baseline year, and 2008 served as the follow-up
period. Process of care and intermediate clinical outcomes
were measured during the follow-up year (i.e., 2008).
Data source
The Humana Medicare Advantage Part D database
(MAPD) from January 01, 2007 through December 31,
2011 was used for this study. The Humana claims database
consists of more than 12 million current and previous
enrollees among which approximately 2 million enrollees
are from MAPD plans. This study used medical, prescrip-
tion, laboratory claims and person enrollment summary
files. The medical claims contained information related to
the type of plan, treatment date, type of admission (trauma,
elective, emergency etc.), inpatient length of stay, diagnosis
and procedural codes, and total Medicare allowable charges
associated with each claim. Prescription claims included in-
formation on prescription fill date, medication dispensed,
quantity of medication dispensed, net amount paid by
Humana and out-of-pocket costs for enrollees. The labora-
tory Claims contained information on lab test identifying
codes, lab results and abnormal value indicator. However,
laboratory results are available only for approximately
30 % of the laboratory claims. The patient enrollment
summary file included information on the MAPD enrol-
lees’ age, sex, race/ethnicity, and enrollment dates.
Study population
The study population consisted of elderly Medicare
beneficiaries (≥65 years) with T2DM. Elderly Medicare
beneficiaries with T2DM were identified by the presence
of a minimum of one inpatient or two outpatient visits
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(at least of 30 days apart) with a primary or secondary
diagnosis of T2DM [International Classification of Diseases
9th Modification (ICD-9-CM) code: 250.x0 or 250.x2] [14].
Inclusion criteria
Other inclusion criteria were: (i) continuous enrollment
of 24 months (12-month baseline and 12-month follow-
up); and (ii) receipt of at least one oral antidiabetic drug
(OAD) or insulin during the baseline year.
Dependent variables
Process of care The three processes of care measures
used in this study included: (i) HbA1c testing; (ii) lipid
testing; and (iii) nephropathy screening. These measures
were considered to meet the American Diabetes Associ-
ation (ADA) guidelines if: (1) HbA1c testing was con-
ducted at least two times a year with a gap of at least
three months; (2) lipid testing was conducted at least
once a year; and (3) nephropathy screening was con-
ducted at least once a year [15]. A detailed description
of the CPT and HCPCS codes are provided in Appendix.
Intermediate clinical outcomes
Glycemic control
HbA1c > 9 % represents poor glycemic control and is
considered to be a poor performance marker among all
elderly individuals with T2DM [16]. One study has used
HbA1c < 7 % as representative of optimal glycemic con-
trol [16]. However, due to the risk of hypoglycemia, less
stringent criteria of HbA1C < 8 % is often considered as
acceptable glycemic control among elderly individuals
with comorbid conditions, or long standing diabetes or
multiple medication use [17]. Therefore, glycemic con-
trol outcomes were classified into two groups based on
HbA1c values as follows: (i) < 8 % and (ii) ≥ 8 % only
among those with available HbA1c values during follow-
up year (N = 4,983).
Lipid control
Lipid control outcomes were based on Low Density
Lipoprotein Cholesterol (LDL-C), High Density Lipopro-
tein Cholesterol (HDL-C), triglycerides, and total choles-
terol. These lipid control outcomes were categorized
based on the American Diabetes Association guidelines
[15]. LDL-C was categorized as follows: (i) <100 mg/dl
and (ii) ≥ 100 mg/dl. HDL-C was categorized into two
for both men and women as follows: (i) ≤ 50 mg/dl;
and (ii) > 50 mg/dl. Triglycerides were classified into:
(i) <150 mg/dl; and (ii) ≥ 150 mg/dl. Total cholesterol
was divided into groups as follows: (i) < 200 mg/dl; and
(ii) ≥ 200 mg/dl. Again these were restricted to individuals
with available LDL-C (N = 2,497), HDL-C (N = 4,833),
total cholesterol (N = 2,543) and triglycerides (N = 2,535)
values during the follow-up year.
Key independent variable: presence of PD
The key independent variable for all analyses was pres-
ence or absence of PD. Identification of PD was achieved
by using ICD-9-CM code of 332.xx during the baseline
year. The diagnosis of PD was ascertained by the pres-
ence of at least one inpatient or two outpatient visits (30
days apart) with a primary or secondary diagnosis of PD
(ICD-9-CM code: 332.xx) [18].
Independent variables
Patient complexities
According to the American Geriatric Society (AGS)
guidelines, individuals having specific conditions such as
cognitive impairment, depression, fall and falls risk,
polypharmacy, and urinary incontinence should be pro-
vided individualized treatment [19]. These characteristics
were measured during the baseline period. Elderly Medi-
care beneficiaries were considered to have cognitive im-
pairment due to physical illnesses if they had a diagnosis
of Huntington’s disease, delirium, dementia, amnestic
and other cognitive disorders; whereas if they have a
diagnosis of bipolar disorder, schizophrenia and other
psychotic disorders, they were considered to have cogni-
tive impairment due to mental illnesses. Elderly Medicare
beneficiaries were considered to have any cognitive im-
pairment if they had either mental and/or physical cogni-
tive impairment. To identify accidental falls, E-codes E880
through E888 were used whereas V-code V15.88 was used
as a proxy measure for falls risk [20]. Number of
therapeutic classes of prescribed medications was used to
define polypharmacy, and was categorized into quintiles:
(i) 0–0, (ii) 1–1, (iii) 2–3, (iv) 4–5, and (v) 6–31.
Dominant comorbid conditions
Using the framework of Kerr and Piette, cancer, end stage
renal disease, and end stage liver disease were included as
a dominant comorbid condition in this study [21].
Other independent variables
The current study adapts elements from the Vector
model of Complexity proposed by Safford and colleagues
to categorize other independent variables associated with
complex comorbidities [22]. Socio-economic variables con-
sisted of (i) Medicare prescription drug coverage gap; and
(ii) insurance status (Private Fee-for-service, Health Main-
tenance Organization, and other insurance). Environmental
factors consisted of (i) region (South, Mid-West, and
Other regions). The cultural factors was defined by
race/ethnicity (Whites, African- Americans, Hispanics,
and Others). The behavioral factors consisted of
baseline emergency room visits, and baseline home
health visits.
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Statistical analyses
Unadjusted differences in process and intermediate clin-
ical outcomes among elderly individuals with and without
Parkinson’s disease were determined using chi-square
tests. Conditional Logistic regression analyses and condi-
tional multinomial logistic regression analyses were con-
ducted for binary dependent variables and dependent
variables with more than two levels respectively. As 30 %
of the study cohort did not have laboratory values, sample
selection models were used to test selection bias among
individuals with and without laboratory values for misspe-
cification bias due to non-randomly missing data. This
was accomplished using “heckprob” selectivity corrected
regression. These models consisted of a selection equation
in which the presence or absence of laboratory values
were modelled. In the outcome equation, the intermediate
clinical outcomes were modelled. For example, for HbA1c
control, a logistic regression on the presence or absence of
HbA1c values was conducted. In the outcome equation,
glycemic control (<8 % and ≥ 8 %) was modelled. The
Wald test of independence showed that the chi-square
probability value was 0.7968 indicating that there is no
influence of unobserved variables on glycemic control
outcome in this dataset. Similar findings were observed
with the lipid outcomes. Therefore, we report results from
analyses among elderly individuals with available HbA1C
values and lipid values.
Propensity score matching
Before propensity score matching, there were 2,727
individuals with PD and diabetes (cases), and 249,763
individuals with diabetes only (controls). After propensity
score matching and removing pairs with inexact matches,
there were 2,703 individuals with PD and diabetes and
8,109 individuals with diabetes only (1:3 case to control
matching). The cohort development is depicted in Fig. 1.
Age and Diabetes Complications Severity Index (DCSI)
total were continuous variables and the group differences
in these two variables were ascertained by t-tests. For
gender the group differences were ascertained by using
chi-square. The number of individuals with PD before and
after matching in each year are different because of the
fact that we found that 1,282 individuals without PD in
previous years were diagnosed with PD in the following
year, and as these individuals were included in the control
dataset for a particular year, they were deleted from the
control dataset so that we do not have overlap between
case and control group during matching. For each year,
the individuals with PD in the matched sample were
unique cases.
The two groups were matched on age, gender and
DCSI scores. The c-statistics of the logistic regression to
calculate propensity score for each year were found to
be satisfactory (around 0.70). From Tables 1 and 2, it
can be noted that, before propensity score matching, the
two groups differed significantly from each other in
terms of age, DCSI total and gender distribution. Before
matching, among individuals with T2DM and PD, the
total mean DCSI score was significantly higher com-
pared to those with only diabetes. In terms of age, indi-
viduals with PD and diabetes had a significantly higher
mean age as compared to those with diabetes only prior
to propensity score matching. The PD and diabetes
group had significantly higher number of males as com-
pared to the group with diabetes only before matching.
The propensity score matched sample was found to be
well balanced in terms of the variables that were used to
match the two groups. After matching there were no
significant differences between the two groups in
terms of age, DCSI and gender. From the bottom panel of
Tables 1 and 2, it can be noted that when the 4 panels
(2007–2008, 2008–2009, 2009–2010, and 2010–2011)
were stacked, there were no statistically significant group
differences in terms of age, gender and DCSI.
Results
Description of study sample by PD status
Table 3 exhibits baseline characteristics of T2DM elderly
individuals with and without PD. There was significantly
higher proportion of African-Americans (14.4 %) among
individuals without PD. Overall, both the groups had
higher proportions of whites (75.7 % and 74.3 % of indi-
viduals with and without respectively). In terms of re-
gion and plan types, there were higher proportion of
individuals in the South region (around 75 %) and
Health Maintenance Organizations in both the groups
(around 48 %). There was significantly higher proportion
of individuals who did not reach donut hole (56.6 %)
among individuals with only diabetes, whereas the group
with PD and diabetes had higher proportions of individ-
uals entering (44.9 %) and having entry and exit infor-
mation regarding donut hole (17.7 %). Individuals with
PD and diabetes had significantly greater proportion of
polypharmacy users in the higher quintiles (4–5, and
6–31). With respect to the conditions specific to eld-
erly individuals, individuals with PD and diabetes had
significantly higher proportion of urinary incontinence
(10.4 %), major depressive disorders (26.7 %), cognitive
impairment (33.4 %), and falls and falls risk (9.9 %).
Individuals with PD had higher proportion of baseline
emergency room (55.5 %) and baseline home health
visit (60.9 %).
Bivariate and multivariate analyses of process of
care and intermediate clinical outcomes
Table 4 summarizes the findings of bivariate and multi-
variate analyses in terms of process of care measures
and intermediate clinical outcomes. Overall, 66.84 % had
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ADA recommended HbA1c testing. A lower percentage
of individuals with PD received HbA1c testing (63.7 %)
compared to those without PD (67.9 %, P-value <0.001).
An overwhelming majority of individuals with T2DM re-
ceived lipid testing (84.65 %). A lower percentage of eld-
erly individuals with PD (80.4 %) received lipid testing
compared to those without PD (86.1 %, p-value < 0.001).
No statistically significant differences were observed in
the two groups in terms of nephropathy screening.
Among elderly individuals with available HbA1C values,
an overwhelming majority had HbA1C value of < 8 % in
both individuals with PD (86 %) and without PD (83.8 %).
Elderly individuals with PD had statistically significantly
better intermediate clinical outcomes compared to
Fig. 1 Cohort development
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those without PD in terms of LDL-C < 100 mg/dl
(75.5 % vs. 69.8 %), triglycerides < 150 mg/dl (63.8 %
vs. 58.6 %), total cholesterol < 200 mg/dl (87.2 % vs. 83 %)
and HDL-C ≥ 50 mg/dl (39.8 % vs. 35.7 %).
The upper panel of the right hand portion of Table 4
shows the results of conditional logistic regression ana-
lyses conducted with HbA1c testing as the dependent
variable adjusting for the matched pair design. After
controlling for Parkinson’s disease, race/ethnicity, region,
plan-type, donut hole, polypharmacy, urinary incontinence,
depression, falls and fall risk, cognitive impairment due to
physical conditions, cognitive impairment due to mental
conditions, dominant conditions, baseline emergency room
visits, baseline home health visits and adjusting for the
matched pair design, it was observed that individuals with
PD were 12 % (AOR: 0.88, 95 % CI: 0.79-0.97) and 18 %
(AOR: 0.82, 95 % CI: 0.72-0.94) less likely to meet the
annual ADA recommended HbA1c and lipid testing
Table 1 Distribution of matching variables before and after Propensity Score Matching (PSM) in each year
Before Matching After Matching
2007
PD No PD PD No PD
N = 775 N = 101,306 Sig N = 775 N = 2,325 Sig
Age (Mean ± SD) 74.57 (±4.96) 72.56 (±5.02) *** 74.57 (±4.96) 74.56 (±4.95)
DCSI Total (Mean ± SD) 3.42 (±2.38) 2.22 (±2.11) *** 3.42 (±2.38) 3.42 (±2.38)
Gender ***
Male (N, %) 461 (59.48 %) 47,844 (47.23 %) 461 (59.48 %) 1,385 (59.57 %)
Female (N, %) 314 (40.52 %) 53,462 (52.77 %) 314 (40.52 %) 940 (40.43 %)
2008
PD No PD PD No PD
N = 949 N = 120,136 Sig N = 571 N = 1,713 Sig
Age (Mean ± SD) 75.16 (±5.18) 72.80 (±5.19) *** 74.95 (±5.32) 74.94 (±5.32)
DCSI Total (Mean ± SD) 3.46 (±2.34) 2.31 (±2.15) *** 3.42 (±2.33) 3.42 (±2.34)
Gender ***
Male (N, %) 535 (56.38 %) 56,985 (47.43 %) 307 (53.77 %) 919 (53.65 %)
Female (N, %) 414 (43.62 %) 63,151 (52.57 %) 264 (46.23 %) 794 (46.35 %)
2009
PD No PD PD No PD
N = 1,208 N = 144,290 Sig N = 667 N = 2,001 Sig
Age (Mean ± SD) 75.24 (±5.48) 73.00 (±5.37) *** 74.54 (±5.61) 74.59 (±5.60)
DCSI Total (Mean ± SD) 3.59 (±2.38) 2.44 (±2.19) *** 3.57 (±2.47) 3.54 (±2.41)
Gender ***
Male (N, %) 710 (58.77 %) 68,650 (47.58 %) 382 (57.27 %) 1,153 (57.62 %)
Female (N, %) 498 (41.23 %) 75,640 (52.42 %) 285 (42.73 %) 848 (42.38 %)
2010
PD No PD PD No PD
N = 1,384 N = 170,941 Sig N = 714 N = 2,142 Sig
Age (Mean ± SD) 75.43 (±5.63) 73.20 (±5.48) *** 74.77 (±5.88) 74.79 (±5.87)
DCSI Total (Mean ± SD) 3.66 (±2.43) 2.49 (±2.21) *** 3.65 (±2.44) 3.64 (±2.42)
Gender ***
Male (N, %) 815 (58.89 %) 80,924 (47.34 %) 416 (58.26 %) 1,250 (58.36 %)
Female (N, %) 569 (41.11 %) 90,017 (52.66 %) 298 (41.74 %) 892 (41.64 %)
Note: This table presents the matching variable distribution before and after propensity score matching by individual year
DCSI Diabetes Complications Severity Index
***P < 0.001; **0.001 ≤ P < .01; *0.01 ≤ P < 0.05
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respectively compared to individuals without PD. However,
there were no statistically significant difference between in-
dividuals with and without PD in terms of nephropathy
testing (AOR: 0.99, 95 % CI: 0.88-1.10).
The lower panel of the right hand portion of Table 4
shows the results from conditional multinomial logistic
regression with glycemic control as the dependent variable.
After adjusting for Parkinson’s disease, race/ethnicity, re-
gion, plan-type, donut hole, polypharmacy, urinary incon-
tinence, depression, falls and fall risk, cognitive impairment
due to physical conditions, cognitive impairment due to
mental conditions, dominant conditions, baseline emer-
gency room visits, baseline home health visits and matched
pair design, it was observed that individuals with PD were
34 % (AOR: 1.34, 95 % CI: 1.10-1.63) more likely to have
better glycemic control (HbA1c < 8 %) compared to those
without PD. Individuals with PD were higher likely to have
better outcomes in terms of LDL-C (<100 mg/dl) (AOR:
1.29, 95 % CI: 1.06-1.59), triglyceride (<150 mg/dl) (AOR:
1.31, 95 % CI: 1.06-1.62), total cholesterol (<200 mg/dl)
(AOR: 1.46, 95 % CI: 1.08-1.97) and HDL-C (≥50 mg/dl)
(AOR: 1.20, 95 % CI: 1.04-1.39).
Discussion
This study examined the association between PD and
process and intermediate clinical outcomes of diabetes
care among elderly individuals with T2DM. Results from
this study indicated that among individuals with T2DM,
those with PD did not receive the ADA recommended
HbA1c and lipid testing compared to those without PD.
These findings suggest that, PD is a barrier to achieving
clinically recommended process of care measures. We
can speculate the reasons as to why those with PD did
not achieve the ADA recommended HbA1c and lipid
testing. Some of the reasons which may lead to not
achieving the ADA recommended HbA1c and lipid test-
ing can be that elderly Medicare beneficiaries may not
be aware of the benefits of meeting these goals, or there
can be a gap in patient-provider communication, or the
elderly Medicare beneficiaries may not be visiting their
physicians on a regular basis [23]. Some of the ways in
which these barriers can be overcome include educating
patients and helping them to attend group consultations
by healthcare providers [24]. Future studies should ex-
plore the possible reasons why elderly individuals with
co-occurring T2DM and PD are not being able to
achieve the ADA recommended process of care goals.
A noteworthy finding from our study is the relation-
ship between PD and intermediate clinical outcomes of
diabetes care. For glycemic and lipid outcomes, elderly
individuals with PD were more likely to achieve control
compared to those without PD. A plausible explanation
for better outcomes among those with PD could be due
to pathophysiological conditions of the two diseases. For
example, it has been suggested that insulin resistance
and insulin deficiency, which are the cardinal character-
istics of T2DM, can lead to neurodegeneration [9–11]. It
is possible that given the risk of neurodegeneration due
to T2DM, the providers may be aggressively treating in-
dividuals with T2DM and PD for better glycemic and
lipid outcomes in order to prevent further neurodegen-
eration. The findings from this study are consistent with
a study conducted among elderly veterans, which showed
that veterans with PD were more likely to receive
overall good outcomes for all three intermediate clinical
outcomes - glycemic, blood pressure and low density
lipoprotein-cholesterol combined (adjusted OR, 2.17; 95 %
CI, 1.96-2.39) [6]. One of the similarities between VA and
the Medicare Advantage (MA) plans is that they follow
the Integrated Delivery System (IDS) model or the “coor-
dinated care plan” approach. In the IDS model, the pri-
mary physician serves as the gate-keeper and maintains
proper referral systems. The coordination of care among
different types of specialists (Endocrinologists, Neurolo-
gists etc.) is ensured in the IDS models which in turn
could lead to better management of individuals with PD.
One can speculate that such coordination may involve
comprehensive geriatric assessment (CGA) tools, which in
turn can lead to better intermediate clinical outcomes
among elderly beneficiaries with T2DM and PD.
However, the findings from this study is inconsistent
with the findings from the study using the INTERMED
classification system for case complexity which found
that among individuals with T2DM, greater complexity
was associated with higher HbA1c values [7]. The
INTERMED classification system utilized different fac-
tors such as biological, psychosocial and health care
related aspects of T2DM to classify patient complexity
and had only 61 patients in the study. The results from
this study [7] presented were in the preliminary forms
and it required further validation. Hence, it is possible
that due to different classification system used to
Table 2 Distribution of matching variables after PSM
Humana Medicare Advantage Part-D Database (2007–2010 stacked)
PD No PD
N = 3,665 N = 10,995 Sig
Age (Mean ± SD) 74.84 (±5.56) 74.86 (±5.56)
DCSI Total (Mean ± SD) 3.53 (±2.43) 3.52 (±2.41)
Gender
Male (N, %) 2,092 (57.08 %) 6,296 (57.26 %)
Female (N, %) 1,573 (42.92 %) 4,699 (42.74 %)
Note: This table is based on propensity score matched data (matched on baseline
age, gender and Diabetes Complications Severity Index) from Humana Medicare
Prescription-Drug Plan of 10,812 elderly Medicare beneficiaries (2,703 cases with
Parkinson’s disease and type-2 Diabetes Mellitus and 8,109 controls with only
type-2 Diabetes Mellitus) during the period of January 2007 to December 2011
DCSI Diabetes Complications Severity Index
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determine patient complexity, greater risk of poor dia-
betes control among individuals with higher complexity
was observed.
Strengths and limitations
Strengths of this study include the use of large sample
size, nationwide sample of commercially insured elderly
individuals, exhaustive list of variables, availability of
laboratory values and use of a robust study design.
As with other studies, this study also has limitations.
Findings from this study cannot be generalizable to other
populations or settings (e.g., fee-for-service Medicare bene-
ficiaries). Laboratory values are available for only one-third
of the population. Unmeasured confounders such lifestyle
risk factors (e.g., body mass index and smoking status),
physician specialty, duration and severity of PD could
influence the study outcomes.
Conclusion
To the best of author’s knowledge, this is the first study
to examine the influence of the presence of a chronic
illness with complexity such as PD on the process and
outcomes of diabetes care. Individuals with PD and
diabetes were less likely to achieve ADA recom-
mended annual HbA1c and lipid testing goals com-
pared to those with diabetes but without PD. Future
research needs to explore the reasons for lower rates
of HbA1C and lipid testing among elderly individuals
with T2DM and PD. However, among individuals with
PD, the intermediate glycemic and lipid outcomes
were better compared to those without PD. These
findings suggest that the integrated delivery system
coupled with the CGA approach of MA plans may be
beneficial to elderly with PD.
Table 3 Baseline characteristics of Elderly Medicare Beneficiaries
after matching
PD Col % No PD Col % Sig
Race/Ethnicity ***
White 2,047 75.7 6,025 74.3
African American 293 10.8 1,168 14.4
Other 169 6.3 446 5.5
Unknown 194 7.2 470 5.8
Region ***
South 1,806 66.8 5,223 64.4
Midwest 604 22.3 1,778 21.9
Other Region 293 10.8 1,108 13.7
Plan Type ***
HMO 1,315 48.6 3,648 45.0
PFFS 918 34.0 2,536 31.3
Others 470 17.4 1,925 23.7
Donut Hole ***
No DH 1,012 37.4 4,590 56.6
Beg DH 1,213 44.9 2,937 36.2
Beg/End DH 478 17.7 582 7.2
Polypharmacy quintile ***
0 – 0 357 13.2 1,644 20.3
1 – 1 454 16.8 1,749 21.6
2 – 3 539 19.9 1,818 22.4
4 – 5 620 22.9 1,570 19.4
6 - 31 733 27.1 1,328 16.4
Urinary Incontinence ***
Yes 280 10.4 353 4.4
No 2,423 89.6 7,756 95.6
Major Depressive Disorder ***
Yes 722 26.7 963 11.9
No 1,981 73.3 7,146 88.1
Cognitive Impairment ***
Yes 904 33.4 686 8.5
No 1,799 66.6 7,423 91.5
Dominant Conditionsa
Yes 340 12.6 989 12.2
No 2363 87.4 7120 87.8
Falls and falls risk ***
Yes 268 9.9 354 4.4
No 2435 90.1 7755 95.6
Baseline ER visit ***
Yes 1500 55.5 3172 39.1
No 1203 44.5 4937 60.9
Table 3 Baseline characteristics of Elderly Medicare Beneficiaries
after matching (Continued)
Baseline HH visit ***
Yes 1647 60.9 3736 46.1
No 1056 39.1 4373 53.9
Note: Based on propensity score matched data (matched on baseline age,
gender and Diabetes Complications Severity Index) from Humana Medicare
Prescription-Drug Plan of 10,812 elderly Medicare beneficiaries (2,703 cases
with Parkinson’s disease and type-2 Diabetes Mellitus and 8,109 controls with
only type-2 Diabetes Mellitus) during the period of January 2007 to
December 2010
PD Parkinson’s disease, ER Emergency Room, HH Home Health, HMO Health
Maintenance Organization, PFFS Private Fee for Service, Sig Significance,
LDL Low Density Lipoprotein, HDL High Density Lipoprotein, Trigly Triglyceride,
chol Cholesterol
Asterisks represent significant group differences in HbA1c testing according to
American Diabetes Association (ADA) guidelines using conditional logistic
regression adjusting for the matched pair design
***P < 0.001; **0.001 ≤ P < .01; *0.01 ≤ P < 0.05
aDominant conditions consisted of cancers, end stage renal disease, end stage
liver disease, and amputations
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Appendix
HbA1c testing
Individuals with HbA1c testing at least two times a year
(with a gap of at least one month) will be considered as
meeting standard of care for diabetes management.
HbA1c testing will be identified by the following Current
Procedural Terminology (CPT) codes.
a. CPT codes: 83036, 83037 (Source : HEDIS, 2012)
b. CPT Category II : 3044F, 3045F, 3046F, 3047F
(Source : HEDIS, 2012)
Lipid testing
Individuals who were tested at least once a year will
be considered as meeting standard of care for dia-
betes management. Lipid testing will be identified by
the following Current Procedural Terminology (CPT)
codes.
a. CPT codes: 80061, 83700, 83701, 83704, 83721,
83715, 83716, 83718, 82465, and 84478 (Source:
HEDIS, 2012)
b. CPT Category II: 3048F, 3049F, 3050F
Table 4 Bivariate and multivariate analyses of process of care and intermediate clinical outcomes
Humana Medicare Advantage Part D database (2007–2011)
PD Col % No PD Col % Sig
N = 2,703 N = 8,109 AORa 95% CI Sig
HbA1c Testing *** HbA1c Testing
Yes 1,722 63.70 5,505 67.90 Parkinson 0.88 [0.79,0.97] *
No 981 36.30 2,604 32.10 No Parkinson
Lipid Testing *** Lipid Testing
Yes 2,174 80.40 6,978 86.10 Parkinson 0.82 [0.72,0.94] **
No 529 19.60 1,131 13.90 No Parkinson
Nephropathy Screening Nephropathy Screening
Yes 2,027 75.00 6,015 74.20 Parkinson 0.99 [0.88,1.10]
No 676 25.00 2,094 25.80 No Parkinson
Intermediate Clinical Outcomes among those with Available Lab Values
PD Col % No PD Col % Sig AORb 95% CI Sig
HbA1c groups N = 1,247 N = 3,736 HbA1c <8%
> = 8% 174 14.00 604 16.20 Parkinson 1.34 [1.10,1.63] **
<8% 1,073 86.00 3,132 83.80 No Parkinson
LDL-C groups N = 559 N = 1938 ** LDL-C <100 mg/dL
> = 100 mg/dl 137 24.50 586 30.20 Parkinson 1.29 [1.06,1.59] *
<100 mg/dl 422 75.50 1,352 69.80 No Parkinson
Triglyceride groups N = 558 N = 1977 * Triglyceride <150 mg/dL
> = 150 mg/dl 202 36.20 819 41.40 Parkinson 1.31 [1.06,1.62] *
<150 mg/dl 356 63.80 1,158 58.60 No Parkinson
Total Cholesterol groups N = 561 N = 1982 * Total Cholesterol < 200 mg/dL
> = 200 mg/dl 72 12.80 336 17.00 Parkinson 1.46 [1.08,1.97] *
<200 mg/dl 489 87.20 1,646 83.00 No Parkinson
HDL-C groups N = 1157 N = 3676 * HDL-C≥ 50 mg/dL
<50 mg/dl 696 60.20 2,364 64.30 Parkinson 1.20 [1.04,1.39] *
> = 50 mg/dl 461 39.80 1,312 35.70 No Parkinson
Note: Based on propensity score matched data (matched on baseline age, gender and Diabetes Complications Severity Index) from Humana Medicare
Prescription-Drug Plan of 10,812 elderly Medicare beneficiaries (2,703 cases with Parkinson’s disease and type-2 Diabetes Mellitus and 8,109 controls with only
type-2 Diabetes Mellitus) during the period of January 2007 to December 2011 (except the bottom panel)
PD Parkinson’s disease, Sig Significance, LDL Low Density Lipoprotein, HDL High Density Lipoprotein, Trigly Triglyceride, yr Year, chol Cholesterol, AOR Adjusted
Odds Ratio, CI Confidence Interval
***P < 0.001; **0.001 ≤ P < .01; *0.01 ≤ P < 0.05
aAOR obtained from conditional logistic regression
bAOR obtained from multinomial conditional logistic regression. Reference groups: ≥8% HbA1c; LDL-C ≥ 100 mg/dL; Triglyceride ≥ 150 mg/dL; LDL-C ≥ 50 mg/dL;
Total Cholesterol ≥ 200mg/dL
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Nephropathy screening
Individuals who were screened at least once a year
for urine albumin and serum creatinine will be
considered as meeting standard of care for diabetes
management. Nephropathy screening will be identified
using the following Current Procedural Terminology
(CPT) codes.
a. CPT codes: 81000, 81001, 81002, 81003, 36800,
36810, 36815, 50300, 50340, 50360, 50365, 50370,
50380, 90920, 90921, 90924, 90925, 90935, 90937,
90945, 90947, 90989, 90993, 90997, and 90999
82579 for serum creatinine lab; 82042, 82043,
82044, 84156 (Source: HEDIS, 2012)
b. CPT Category II: 3060F, 3061F (Source: HEDIS, 2012)
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